WHO criticises lack of big pharma antibiotic R&DBig pharma still continues to look upon antibiotic resistance as somebody else’s problem, the World Health Organization has Share XWHO criticises lack of big pharma antibiotic R&Dhttps://pharmaphorum.com/news/who-bemoans-lack-of-big-pharma-antibiotic-rd/
Lilly targets quarterly deals worth up to $5bn to boost R&DEli Lilly is targeting a deal worth between $1 billion to $5 billion every quarter in 2020 as Share XLilly targets quarterly deals worth up to $5bn to boost R&Dhttps://pharmaphorum.com/news/lilly-targets-quarterly-deals-worth-up-to-5bn-boost-rd/
UK accounts for 12% of cell and gene therapy trials – reportThe UK accounts for over 12% of global cell and gene therapy clinical trials, according to new data Share XUK accounts for 12% of cell and gene therapy trials – reporthttps://pharmaphorum.com/news/uk-accounts-for-12-of-cell-and-gene-therapy-trials-report/
GSK’s CEO Walmsley aiming for six new approvals in 2020GlaxoSmithKline’s CEO Emma Walmsley has said the company hopes to get at least six new drug approvals in Share XGSK’s CEO Walmsley aiming for six new approvals in 2020https://pharmaphorum.com/news/gsks-ceo-walmsley-aiming-for-six-new-approvals-in-2020/
Chasing Astellas, UK’s KaNDy heads to phase 3 with menopause drugUK biotech KaNDy Therapeutics is heading to phase 3 with its non-hormonal menopause drug, after a mid-stage trial Share XChasing Astellas, UK’s KaNDy heads to phase 3 with menopause drughttps://pharmaphorum.com/news/chasing-astellas-uks-kandy-heads-to-phase-3-with-menopause-drug/
AZ axes phase 3 heart disease trial of fish oil drug EpanovaAstraZeneca has axed a large late-stage trial for its heart disease drug Epanova in patients with mixed dyslipidemia Share XAZ axes phase 3 heart disease trial of fish oil drug Epanovahttps://pharmaphorum.com/news/az-axes-phase-3-trial-in-heart-disease/
Experts call for review of innovative cancer therapies to boost survival ratesThere should be an independent review of how advances in cancer treatment are valued and paid for by Share XExperts call for review of innovative cancer therapies to boost survival rateshttps://pharmaphorum.com/news/experts-call-for-review-of-innovative-cancer-therapies-to-boost-survival-rates/
BI buys rights to NASH-targeted tech from Singapore’s EnleofenBoehringer Ingelheim has bought rights to preclinical technology aimed at fibro-inflammatory diseases including the fatty liver disease known Share XBI buys rights to NASH-targeted tech from Singapore’s Enleofenhttps://pharmaphorum.com/news/bi-buys-rights-to-nash-targeted-tech-from-singapores-enleofen/
NorthSea Therapeutics raises $40m to develop NASH drugDutch biotech NorthSea Therapeutics has raised around $40 million in a series B financing round to help it Share XNorthSea Therapeutics raises $40m to develop NASH drughttps://pharmaphorum.com/news/northsea-therapeutics/
